




INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number	10589866
Filing Date	2006-09-19
First Named Inventor	BERCOVIER
Art Unit	1645
Examiner Name	DEVI
Attorney Docket Number	27637U




U.S. PATENTS [Remove](#)

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

[Add](#)




U.S. PATENT APPLICATION PUBLICATIONS [Remove](#)

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

[Add](#)

FOREIGN PATENT DOCUMENTS [Remove](#)

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² i	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button.

[Add](#)

NON-PATENT LITERATURE DOCUMENTS [Remove](#)

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10589866
Filing Date	2006-09-19
First Named Inventor	BERCOVIER
Art Unit	1645
Examiner Name	DEVI
Attorney Docket Number	27637U

/S.D./	1	NIGOU, et al., "Mannosylated Lipoarabinomannans Inhibit IL-12 Production by Human Dendritic Cells: Evidence for a Negative Signal Delivered Through the Mannose Receptor", The Journal of Immunology, vol. 166, pgs. 7477-7485, (2001).	<input type="checkbox"/>
/S.D./	2	NIGOU, et al., "Mycobacterial lipoarabinomannans: modulators of dendritic cell function and the apoptotic response", Microbes and Infection, vol. 4, pgs. 945-953, (2002).	<input type="checkbox"/>
/S.D./	3	OLSON, et al., "Design and Synthesis of a Protein β -Turn Mimetic", J. Am. Chem. Soc., vol. 112, pgs. 323-333, (1990).	<input type="checkbox"/>
/S.D./	4	PINCUS, et al., "Peptides That Mimic the Group B Streptococcal Type III Capsular Polysaccharide Antigen", The Journal of Immunology, vol. 160, pgs. 293-298, (1998).	<input type="checkbox"/>
/S.D./	5	PRINZIS, et al., "Structure and anitgenicity of lipoarabinomannan from Mycobacterium bovis BCG", Journal of General Microbiology, vol. 139, pgs. 2649-2658, (1993).	<input type="checkbox"/>
/S.D./	6	QUESNIAUX, et al., "Toll-Like Receptor 2 (TLR2)-Dependent-Positive and TLR2-Independent-Negative Regulation of Proinflammatory Cytokines by Mycobacterial Lipomannans", The Journal of Immunology, vol. 172, pgs. 4425-4434, (2004).	<input type="checkbox"/>
/S.D./	7	SCHLESINGER, et al., "Binding of the Terminal Mannosyl Units of Lipoarabinomannan from a Virulent Strain of Mycobacterium Tuberculosis to Human Macrophages", Journal of Immunology, vol. 152, pgs. 4070-4079, (1994).	<input type="checkbox"/>
/S.D./	8	SETHI, et al., "Contraction-Mediated Pinocytosis of RGD-Peptide By Dermal Fibroblasts: Inhibition of Matrix Attachment Blocks Contraction and Disrupts Microfilament Organisation", Cell Motility and Cytoskeleton, vol. 52, pgs. 231-241, (2002).	<input type="checkbox"/>
/S.D./	9	SHIRAKAWA, et al., "The Inverse Association Between Tuberculin Responses and Atopic Disorder", Science, vol. 275, pgs. 77-79, (1997).	<input type="checkbox"/>
/S.D./	10	SHIRTCLIFFE, et al., "An inverse correlation between estimated tuberculosis notification rates and asthma symptoms", Respiriology, vol. 7, pgs. 153-155, (2002).	<input type="checkbox"/>
/S.D./	11	SINGH, et al., "Advances in Vaccine Adjuvants for Infectious Diseases", Current HIV Research, vol. 1, pgs. 309-320, (2003).	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10589866
Filing Date	2006-09-19
First Named Inventor	BERCOVIER
Art Unit	1645
Examiner Name	DEVI
Attorney Docket Number	27637U

/S.D./	12	SMITH, et al., "Libraries of Peptides and Proteins Displayed on Filamentous Phage", Methods in Enzymology, vol. 217, pgs. 228-257, (1993).	<input type="checkbox"/>
/S.D./	13	STERN, et al., "Helical epitopes determined by low-stringency antibody screening of a combinatorial peptide library", FASEB J., vol. 11, pgs. 147-153, (1997).	<input type="checkbox"/>
/S.D./	14	TEMKIN, et al., "Tumor necrosis factors in a murine model of allergic peritonitis: effects on eosinophil accumulation and inflammatory mediators' release", Cytokine, vol. 24, pgs. 74-80, (2003).	<input type="checkbox"/>
/S.D./	15	TIBBETTS, et al., "Linear and cyclic LFA-1 and ICAM-1 peptides inhibit T cell adhesion and function", Peptides, vol. 21, pgs. 1161-1167, (2000).	<input type="checkbox"/>
/S.D./	16	VALADON, et al., "Enhancement of ELISAs for screening peptides in epitope phage display libraries", Journal of Immunological Methods, vol. 197, pgs. 171-179, (1996).	<input type="checkbox"/>
/S.D./	17	VON MUTIUS, et al., "International patterns of tuberculosis and the prevalence of symptoms of asthma, rhinitis, and eczema", Thorax, vol. 55, pgs. 449-453, (2000).	<input type="checkbox"/>
/S.D./	18	VYAS, et al., "Structural basis of peptide-carbohydrate mimicry in an antibody-combining site", PNAS, vol. 100, no. 25, pgs. 15023-15028, (2003).	<input type="checkbox"/>
/S.D./	19	WANG, et al., "Epitope Identification and Discovery Using Phage Display Libraries: Applications in Vaccine Development and Diagnostics", Current Drug Targets, vol. 5, pgs. 1-15, (2004).	<input type="checkbox"/>
/S.D./	20	WU, et al., "The Pharmacological Actions of Nicotine on the Gastrointestinal Tract", Journal of Pharmacological Sciences, vol. 94, pgs. 348-358, (2004).	<input type="checkbox"/>
/S.D./	21	YOSHIMURA, et al., "Role of NFκB in antigen presentation and development of regulatory T cells elucidated by treatment of dendritic cells with the proteasome inhibitor PSI", Eur. J. Immunol., vol. 31, pgs. 1883-1893, (2001).	<input type="checkbox"/>
/S.D./	22	ZABROCKI, et al., "Conformational Mimicry. 1. 1,5-Disubstituted Tetrazole Ring as a Surrogate for the Cis Amide Bond", J. Am. Chem. Soc., vol. 110, pgs. 5875-5880, (1988).	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10589866
Filing Date	2006-09-19
First Named Inventor	BERCOVIER
Art Unit	1645
Examiner Name	DEVI
Attorney Docket Number	27637U

/S.D./	23	ZECHEL, et al., "Synthetic glucagon antagonists and partial agonists", Int. J. Peptide Protein Res., vol. 38, pgs. 131-138, (1991).	<input type="checkbox"/>
/S.D./	24	ZUANY-AMORIM, et al., "Suppression of airway eosinophilia by killed mycobacterium vaccae-induced allergen-specific regulatory T-cells", Nature Medicine, vol. 8, no. 6, pgs. 625-629, (2002).	<input type="checkbox"/>
/S.D./	25	MIYAKK, et al., "1,2,3,4-Tetrahydroisoquinoline-3-carboxylic Acid Angiotensin: Synthesis and Angiotensin Converting Enzyme Inhibitory Activity of 1,2,3,4-Tetrahydroisoquinoline-3-carboxylic Acid Derivatives", J. Takeda Res. Labs., vol. 43, pgs. 53-76, (1984).	<input type="checkbox"/>
/S.D./	26	DELUCA, et al., "Parenteral Drug-Delivery Systems", Pharmaceutics and Pharmacy Practice, ch. 8, pgs. 238-250, J.B. Lippincott Co., Philadelphia, Pa., Banker and Chalmers, eds., (1982).	<input type="checkbox"/>
/S.D./	27	TRISSEL, "Intravenous Infusion Solutions", ASHP Handbook on Injectable Drugs, 4th ed., pgs. 622-630, (1986).	<input type="checkbox"/>
/S.D./	28	ENSHELL-SEIJFFERS, et al., "Phage Display Selection and Analysis of Ab-Binding Epitopes", Current Protocols in Immunology, vol. 2, pgs. 9.8.1-9.8.27, (2002).	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button **Add**

EXAMINER SIGNATURE

Examiner Signature	/S. Devi/	Date Considered	12/22/2010
--------------------	-----------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.